Exomas was featured by Ámbito for transforming more than a decade of scientific research into a biotechnology company and securing the funding needed to advance the development of regenerative therapies for neurodegenerative diseases. The article traces the company-building process carried out with SF500, explains its exosome-based technology, and explores its preclinical progress and upcoming challenges.